Pfizer Corporation

Zoetis Services LLC

Genzyme Corporation

Zoetis LLC

Other

Avocent Corporation

Dow Agrosciences LLC

Timothy Allan Johnson

Matthew Frank Brown

Mark Edward Flanagan

Timothy P Martin

Michael R Loso

Rajendran Vairagoundar

Susan M K Sheehan

Joseph Walter Strohbach

William C Lo

Neelu Kaila

Edmund Lee Ellsworth

Peter Laurence Toogood

Benjamin M Nugent

Richard Andrew Ewin

Ruth Elizabeth TenBrink

Rayomand Jal Unwalla

John David Trzupek

Clarke Bentley Taylor

Steven R Blackwell

Matthias Stefan Ober

Joseph Scott Warmus

Andrea Joy Gonzales

Paul D Johnson

Michael P Curtis

Graham M Kyne

Sean Timothy Murphy

Dennis Joseph McNamara

Ye Che

Cheng Cheng

Annette Vitale Brown

Tamim F Braish

Justin Ian Montgomery

Chris Limberakis

Usa Reilly

Jonathan M Babcock

Michael L Vazquez

Mihir D Parikh

Mark J Mitton-Fry

Manjinder Singh Lall

Debra Ann Sherry

Ashley Edward Fenwick

Denton Wade Hoyer

Brian A Duclos

Jonathan Wang

Jason Walther

Susan Mary Kult Sheehan

Neha Shah

Charles Francis Donovan

Donald James Skalitzky

Michael Joseph Melnick

Derek James Sheehan

Mark Stephen Plummer

Loren Michael Price

Daniel Paul Uccello

Christopher Hwang

Jiuyi Lu

Seul-A Bae

Susan M Sheehan

Dan S Crawford, Iii

Jean McLarty

Yukun Ren

Chris Lim-Berakis

Ronald Ross

Denis Billen

Nneka Breaux

Michael Curtis

Ruth E Tenbrink

Richard M Goodwin

Andrea K Haber-Stuk

The present invention is directed to a new fluoro-pyridinone hydroxamic acid phosphates and boronates of Formulae I, II and III wherein Q is selected from the group consisting of —P(O)(OH), —P(O)(OH)(OM), —P(O)(OM)and —P(O)(O)M; Mat each occurrence is a pharmaceutically acceptable monovalent cation; and Mis a pharmaceutically acceptable divalent cation and their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.

Fluoro-pyridinone phosphates and boronates useful as antibacterial agents

Provided herein are methods of predicting the effect of a concentration of a sensitizer on cell viability in a production bioreactor, methods of improving cell viability in a production bioreactor, methods of predicting cell viability in a production bioreactor, and methods for culturing a cell in a production bioreactor.

Methods for improving cell viability in a production bioreactor

Provided herein are methods of culturing a mammalian cell in a liquid medium including poloxamer-188 at a concentration of 1.8 g/L or at a greater concentration than 1.8 g/L more or a liquid medium that includes a poloxamer-188 concentration that is selected based on one or more factors selected from the group of: pore size, pore type, gas flow rate, viable cell density in the medium, and markers related to cell stress.

Methods of culturing a mammalian cell

A improvement to video compression techniques is described in which blocks of video input information are compared in their respective pixel values to corresponding blocks of immediately preceding frames. The blocks are analyzed to determine whether change has occurred in accordance with two tests. First, the pixel values of the block are compared to the pixel values of a preceding block and if a threshold number of pixel values in the block exceed their counterparts by a threshold amount, then the block is assumed to have changed and is communicated via a standard communication protocol, compression technique and media. Second, even if the threshold number of pixels in the block has not changed, the pixel values are compared with their prior frame counterparts to determine if any one pixel value has changed in magnitude more than a second threshold amount. Again, one such pixel is identified, then the block is assumed to have changed and is communicated.

Video compression system

Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, and pharmaceutical compositions containing them.

Pyrrolo[2,3-D]pyrimidine derivatives

The present invention provides novel phenicol derivatives, their use for the treatment of infections in mammals, pharmaceutical composition containing these novel compounds, and methods for the preparation of these compounds.

Phenicol antibacterials

The present invention provides novel phenicol derivatives, their use for the treatment of infections in mammals, pharmaceutical compositions containing these novel compounds, and methods for the preparation of these compounds.

Phenicol antibacterial agents

The invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, thereof, wherein: and pharmaceutically acceptable salts, prodrugs, hydrates, or solvates, thereof, wherein A, B, L-L, A, B, R-R, and m are as defined herein. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and their use in treating a bacterial infection.

Hydroxamic acid derivatives useful as antibacterial agents

The present invention provides novel phenicol derivatives, their use for the treatment of infections in mammals, pharmaceutical composition containing these novel compounds, and methods for the preparation of the compounds of formula I 

The present invention provides novel phenicol derivatives of formula I their use for the treatment of infections in mammals, pharmaceutical composition containing these novel compounds, and methods for the preparation of these compounds.

Described herein are antibacterial compounds of formula I, methods for making the compounds, pharmaceutical compositions containing the compounds and methods of treating bacterial infections utilizing the compounds and pharmaceutical composition.

Tricyclic tetrahydroquinoline antibacterial agents

Growing community of inventors

Richland, MI, United States of America

Timothy Allan Johnson